# US 2009/0270331 A1 · Multi-domain amphipathic helical peptides and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270331 A1
- Document ID: US20090270331A1
- Status: Published application
- Kind: A1
- Application number: 12/497,443
- Filed: 2009-07-02
- Published: 2009-10-29
- Earliest claimed: 2004-10-15
- Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Inventors: Alan T. Remaley; Stephen J. Demosky; John A. Stonik; Marcele J.A. Amar; Edward B. Neufeld; Bryan H. Brewer; Fairwell Thomas
- Web page: https://patentgrep.com/patent/US20090270331A1

## CPC

- C07K 14/775: Apolipopeptides
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.

## Claims

### Claim 1

An isolated nucleic acid molecule encoding a peptide or peptide analog comprising an amino acid sequence as set forth in SEQ ID NO: 3.

### Claim 2 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule encodes a peptide or peptide analog set forth in SEQ ID NO: 3, promotes ABCA1-dependent lipid efflux from cells and is substantially non-cytotoxic.

### Claim 3 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule encodes a peptide or peptide analog of claim 1 and at least one additional peptide domain.

### Claim 4 (depends on 3)

The isolated nucleic acid molecule of claim 3, wherein the additional peptide domain comprises a heparin binding site, an integrin binding site, a P-selectin site, a TAT HIV sequence, a panning sequence, a penatratin sequence, a SAA C-terminus sequence, a SAA N-terminus sequence, a LDL receptor sequence, a modified 18A sequence, an apoA-I Milano sequence, a 6×-His sequence, a lactoferrin sequence, or combinations of two or more thereof.

### Claim 5 (depends on 1)

A pharmaceutical composition, comprising the isolated peptide or peptide analog of the isolated nucleic acid molecule of claim 1 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 5)

A method of treating or inhibiting a dyslipidemic or vascular disorder in a subject, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 5.

### Claim 7 (depends on 6)

The method of claim 6, wherein the dyslipidemic or vascular disorder comprises hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, HDL deficiency, apoA-I deficiency, coronary artery disease, atherosclerosis, thrombotic stroke, peripheral vascular disease, restenosis, acute coronary syndrome, post-perfusion myocardial injury, vasculitis, inflammation, or combinations of two or more thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the dyslipidemic or vascular disorder is hypercholesterolemia.

### Claim 9 (depends on 8)

The method of claim 8, further comprising administering an additional lipid lowering composition.

### Claim 10 (depends on 6)

The method of claim 6, wherein the pharmaceutical composition is delivered on an implant.

### Claim 11 (depends on 7)

The method of claim 7, wherein the pharmaceutical composition is delivered on an implant.

### Claim 12 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition is delivered on an implant.

### Claim 13 (depends on 9)

The method of claim 9, wherein the pharmaceutical composition is delivered on an implant.

### Claim 14 (depends on 1)

An implant coated with the peptide or peptide analog of the isolated nucleic acid molecule of claim 1.

### Claim 15 (depends on 14)

The implant of claim 14, wherein the peptide or peptide analog promotes ABCA1-dependent lipid efflux from cells and is substantially non-cytotoxic.

### Claim 16 (depends on 14)

The implant of claim 14, wherein the peptide or peptide analog further comprises at least one additional peptide domain.

### Claim 17 (depends on 16)

The implant of claim 16, wherein the additional peptide domain comprises a heparin binding site, an integrin binding site, a P-selectin site, a TAT HIV sequence, a panning sequence, a penatratin sequence, a SAA C-terminus sequence, a SAA N-terminus sequence, a LDL receptor sequence, a modified 18A sequence, an apoA-I Milano sequence, a 6×-His sequence, a lactoferrin sequence, or combinations of two or more thereof.

### Claim 18 (depends on 14)

The implant of claim 14 which, when implanted in a heart or peripheral vasculature, treats or inhibits a dyslipidemic or vascular disorder.

### Claim 19 (depends on 1)

The isolated nucleic acid of claim 1 for use in the manufacture of an implant for treating or inhibiting a dyslipidemic or vascular disorder.
